Alternate-Day Buprenorphine Administration. Phase VII - 8

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine if four times a subjects daily maintenance dose will hold for 96 hours without changes in agonist and antagonist effects under open dosing conditions.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Institute on Drug Abuse (NIDA)
• Collaborator: University of Vermont
• Treatments: Buprenorphine

Criteria

Please contact site for information.